Noubar Afeyan bought $75.0M of Generate Biomedicines (GENB)
Executed Mar 2, disclosed Mar 2, the same day.
Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -4.2% (delay-adjusted); from the execution session (Mar 2), -4.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Noubar Afeyan (Director) filed 4 Form 4 reports in the trailing twelve months (2 purchases, 2 sales), most often in Generate Biomedicines, Inc. (GENB). Across 2 priced purchase filings, the average 21-session return was -4.2% from execution and -4.2% from disclosure (delay-adjusted; derived). The largest single filing was $75.0M of GENB (4,687,500 sh across 3 lots, as filed), executed Mar 2.
Healthcare · Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development throug…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→4,687,500 sh across 3 lots
Exec Mar 2
Filed Mar 2 · 5:42 PM ET